HEART路径随机对照试验的一年结局
该随机对照试验纳入282例急诊胸痛成人患者,随机分为HEART路径组和常规诊疗组各141例。HEART路径组使用HEART评分和0、3小时肌钙蛋白进行风险分层。1年主要不良心脏事件发生率在HEART路径组为9.9%(14/141),常规诊疗组为11.3%(16/141),差异无统计学意义(p=0.85)。低风险HEART路径患者中0%(0/66)发生主要不良心脏事件,阴性预测值为100%(95%CI 93%-100%)。1年客观检查率在HEART路径组为63.1%(89/141),常规诊疗组为71.6%(101/141),差异无统计学意义(p=0.16)。
要点
- 低风险HEART路径患者1年主要不良心脏事件发生率为0%(0/66),阴性预测值100%(95%CI 93%-100%)。
- HEART路径组1年主要不良心脏事件发生率为9.9%(14/141),常规诊疗组为11.3%(16/141),差异无统计学意义(p=0.85)。
- HEART路径组1年客观检查率为63.1%(89/141),常规诊疗组为71.6%(101/141),差异无统计学意义(p=0.16)。
- HEART路径组非指数心脏相关住院率为14.9%(21/141),常规诊疗组为10.6%(15/141),差异无统计学意义(p=0.37)。
- HEART路径组非指数心脏相关急诊就诊率为21.3%(30/141),常规诊疗组为16.3%(23/141),差异无统计学意义(p=0.36)。
适用人群与场景
- 急诊科成人胸痛患者,共282例随机分组,每组141例。
处置流程与药物剂量
- HEART路径组:急诊提供者使用HEART评分和肌钙蛋白测量(0和3小时)对患者进行风险分层。
研究设计与关键结果
- 研究类型:随机对照试验,纳入282例急诊胸痛成人患者,随机分为HEART路径组(141例)和常规诊疗组(141例)。
- 主要终点:1年主要不良心脏事件(心源性死亡、心肌梗死或冠状动脉血运重建)发生率在HEART路径组为9.9%(14/141;10例心肌梗死,4例无心肌梗死血运重建),常规诊疗组为11.3%(16/141;1例心源性死亡,13例心肌梗死,2例无心肌梗死血运重建),p=0.85。
- 低风险HEART路径患者中主要不良心脏事件发生率为0%(0/66),阴性预测值100%(95%CI 93%-100%)。
- 1年客观检查(负荷试验或冠状动脉造影)率在HEART路径组为63.1%(89/141),常规诊疗组为71.6%(101/141),p=0.16。
- 非指数心脏相关住院率在HEART路径组为14.9%(21/141),常规诊疗组为10.6%(15/141),p=0.37。
- 非指数心脏相关急诊就诊率在HEART路径组为21.3%(30/141),常规诊疗组为16.3%(23/141),p=0.36。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,HEART路径对1年安全结局(主要不良心脏事件)具有100%阴性预测值,且未增加下游住院或急诊就诊。
- 作者指出,1年客观检查的减少无统计学意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective was to determine the impact of the HEART Pathway on health care utilization and safety outcomes at 1 year in patients with acute chest pain.
METHODS: Adult emergency department (ED) patients with chest pain (N = 282) were randomized to the HEART Pathway or usual care. In the HEART Pathway arm, ED providers used the HEART score and troponin measures (0 and 3 hours) to risk stratify patients. Usual care was based on American College of Cardiology/American Heart Association guidelines. Major adverse cardiac events (MACE-cardiac death, myocardial infarction [MI], or coronary revascularization), objective testing (stress testing or coronary angiography), and cardiac hospitalizations and ED visits were assessed at 1 year. Randomization arm outcomes were compared using Fisher's exact tests.
RESULTS: A total of 282 patients were enrolled, with 141 randomized to each arm. MACE at 1 year occurred in 10.6% (30/282): 9.9% in the HEART Pathway arm (14/141; 10 MIs, four revascularizations without MI) versus 11.3% in usual care (16/141; one cardiac death, 13 MIs, two revascularizations without MI; p = 0.85). Among low-risk HEART Pathway patients, 0% (0/66) had MACE, with a negative predictive value (NPV) of 100% (95% confidence interval = 93%-100%). Objective testing through 1 year occurred in 63.1% (89/141) of HEART Pathway patients compared to 71.6% (101/141) in usual care (p = 0.16). Nonindex cardiac-related hospitalizations and ED visits occurred in 14.9% (21/141) and 21.3% (30/141) of patients in the HEART Pathway versus 10.6% (15/141) and 16.3% (23/141) in usual care (p = 0.37, p = 0.36).
CONCLUSIONS: The HEART Pathway had a 100% NPV for 1-year safety outcomes (MACE) without increasing downstream hospitalizations or ED visits. Reduction in 1-year objective testing was not significant.
参考来源
- Stopyra JP, Riley RF, Hiestand BC, et al. The HEART Pathway Randomized Controlled Trial One-year Outcomes. Acad Emerg Med. 2018. PMID: 29920834. doi:10.1111/acem.13504
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。